http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106317026-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
| filingDate | 2016-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106317026-B |
| titleOfInvention | A kind of compound being able to suppress ErbB/HDAC and preparation method thereof includes its pharmaceutical composition and application thereof |
| abstract | The present invention relates to a kind of compound for being able to suppress ErbB/HDAC and preparation method thereof, include its medical composition and its use.The compound is as shown in Equation 1, the compound or its pharmaceutically acceptable salt, solvate, ester, acid, metabolin or prodrug, or the pharmaceutical composition comprising the compound, it can be used for preparing the preparation of ErbB kinases and HDAC activity inhibitor and the preparation of the disease curative mediated by ErbB kinases or HDAC activation. |
| priorityDate | 2016-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 272.